Behçet’s syndrome is a chronic condition that causes recurring inflammation throughout the body, leading to mouth sores, eye problems, skin rashes, and joint pain. Though there is no cure, treatment can help control symptoms and prevent serious complications like vision loss.

Understanding Treatment Goals for Behçet’s Syndrome

When someone receives a diagnosis of Behçet’s syndrome, the first question that often comes to mind is: what comes next? This rare inflammatory condition requires a thoughtful approach to treatment, one that aims to reduce the frequency and severity of flare-ups while protecting vital organs from long-term damage. The primary goals are to ease discomfort during active periods of the disease, prevent serious complications such as blindness or blood vessel damage, and help patients maintain a good quality of life.^[1][8]

Treatment decisions depend heavily on which parts of the body are affected and how severe the symptoms are. A person experiencing only mouth ulcers will have a very different treatment plan than someone with eye inflammation or vascular involvement. Because Behçet’s can affect so many different organ systems—from the skin and joints to the eyes, brain, and digestive tract—a team of specialists often works together to create an individualized care plan. This team might include a rheumatologist (a doctor who specializes in inflammatory diseases), a dermatologist, an eye doctor, and other specialists as needed.^[6][18]

Medical societies have developed guidelines to help doctors choose the most appropriate treatments. These standard approaches are based on years of clinical experience and research studies. At the same time, scientists continue to explore new therapies through clinical trials—carefully controlled research studies that test experimental drugs and treatment methods. These trials are essential for discovering better ways to manage Behçet’s syndrome and may offer hope for patients who don’t respond well to existing treatments.^[10]

The disease itself follows an unpredictable pattern. Patients often experience periods when symptoms flare up, followed by times of remission when symptoms disappear or become much milder. Over time, especially as people reach their forties, many find that their disease becomes less severe. However, early and aggressive treatment is important to prevent irreversible damage, particularly to the eyes and blood vessels.^[3][10]

Standard Treatment Options

The foundation of Behçet’s syndrome treatment involves medications that reduce inflammation and calm the overactive immune system. The specific drugs prescribed depend on which symptoms are present and how serious they are. For many patients, treatment begins with simpler approaches and becomes more intensive if symptoms don’t improve or if complications develop.^[8]

Topical Treatments for Sores and Skin Problems

For patients whose main complaint is painful mouth or genital ulcers, topical medications applied directly to the sores often provide relief. These include corticosteroid creams, gels, or rinses that reduce local inflammation and pain. Triamcinolone acetonide is commonly used for mouth ulcers, while betamethasone ointment may be applied to genital sores. Special mouthwashes containing corticosteroids and other soothing agents can make eating and drinking less painful during flare-ups. For the eyes, corticosteroid drops may be prescribed for mild inflammation.^[8][9][11]

These topical treatments have the advantage of working right where they’re needed, with fewer effects on the rest of the body. Most people tolerate them well, though long-term use of corticosteroid creams can sometimes cause skin thinning in the treated area.^[11]

Colchicine for Mucocutaneous Disease

Colchicine, a medication traditionally used for gout, has proven helpful for preventing recurrent mouth and genital ulcers as well as certain skin manifestations like erythema nodosum (tender red bumps, usually on the legs). This drug works by interfering with inflammatory processes at the cellular level. It’s often one of the first systemic medications tried because it has a relatively mild side effect profile. However, some patients may experience digestive upset, including diarrhea and abdominal discomfort.^[6][9][11]

Apremilast: The First FDA-Approved Treatment

In a significant development, apremilast (brand name Otezla) became the first medication approved by the U.S. Food and Drug Administration specifically for treating oral ulcers in adults with Behçet’s disease. This oral medication is a phosphodiesterase 4 inhibitor, which means it works by blocking a specific enzyme involved in inflammation. Patients typically take 30 milligrams twice daily. The approval was based on a clinical trial called RELIEF, which showed that apremilast reduced the number and pain of oral ulcers compared to placebo. This represents an important treatment option, especially for patients whose mouth sores significantly affect their quality of life.^[9][14][18]

Systemic Corticosteroids

When topical treatments aren’t enough, or when more serious symptoms appear, doctors may prescribe oral corticosteroids such as prednisone. These powerful anti-inflammatory drugs affect the entire body and can quickly control severe inflammation. They’re particularly useful during acute flare-ups or when vital organs are threatened. However, corticosteroids come with a long list of potential side effects when used for extended periods, including weight gain, mood changes, high blood pressure, increased infection risk, weakened bones (osteoporosis), stomach ulcers, elevated blood sugar, and eye problems like glaucoma and cataracts.^[8][11]

Because of these risks, doctors try to use the lowest effective dose for the shortest possible time. Many patients need additional medications to help manage the disease and allow the corticosteroid dose to be reduced—a strategy called “steroid sparing.”^[11]

Immunosuppressive Medications

For patients with more severe disease, particularly those with eye involvement, vascular complications, or neurological symptoms, stronger immunosuppressive drugs become necessary. These medications work by dampening the immune system’s activity, which reduces the inflammation that causes symptoms. The most commonly used immunosuppressants in Behçet’s include:

Azathioprine is widely considered the first-line systemic treatment for many manifestations of Behçet’s, especially eye disease. It helps prevent recurrent inflammation and is often used in combination with corticosteroids initially, then continued alone for maintenance. Blood tests are needed regularly to monitor for potential effects on blood cell counts and liver function.^[8][14]

Cyclosporine and tacrolimus are powerful immunosuppressants sometimes used for severe eye inflammation or other serious manifestations. They require careful monitoring because they can affect kidney function and blood pressure. Cyclosporine is particularly effective for posterior uveitis (inflammation in the back of the eye) and may be combined with azathioprine and corticosteroids in severe cases.^[8][11]

Cyclophosphamide is reserved for the most severe and life-threatening complications, such as major blood vessel involvement or severe neurological disease. It’s a very potent medication with potentially serious side effects, including effects on fertility, so it’s used only when necessary.^[11]

Methotrexate and mycophenolate are other immunosuppressive options that may be used depending on the specific symptoms and how well a patient tolerates other medications.^[11]

Biological Therapies

Biological therapies represent a newer class of treatment that targets specific parts of the immune system involved in causing inflammation. The most studied biologics for Behçet’s are tumor necrosis factor-alpha (TNF-α) inhibitors. These medications block TNF-α, a protein that plays a key role in the inflammatory process. The TNF inhibitors most commonly used for Behçet’s include infliximab (Remicade) and adalimumab (Humira). These drugs are given by injection or infusion and have shown particular effectiveness for severe eye disease, gastrointestinal involvement, and vascular complications that haven’t responded to conventional treatments.^{[6][9][11][18]}

An expert panel has even recommended considering infliximab and adalimumab as first-line treatments for severe ocular (eye) manifestations, often in combination with other immunosuppressants. These biologics can be quite effective but come with their own risks, including increased susceptibility to infections and potential reactions to the infusions.^[14]

Interferon-alfa is another biological agent used primarily in Europe and Japan for severe eye disease. It can be used alone or combined with corticosteroids. Studies from Germany have reported good long-term results and improved vision in patients with severe ocular Behçet’s who were treated with interferon-alfa.^[8][14]

Treatment Duration and Monitoring

The length of treatment varies considerably from person to person. Some patients with mild disease may only need medication during flare-ups, while others require long-term therapy to keep symptoms under control and prevent complications. As mentioned earlier, many people find that their disease becomes less active over time, particularly after reaching middle age. This may allow for gradual reduction of medications under careful medical supervision.^[8][10]

Regular follow-up appointments are essential. Eye examinations are particularly important because eye inflammation can progress silently and cause permanent damage before symptoms become obvious. Blood tests help monitor for medication side effects and disease activity. In some cases, imaging studies may be needed to check on blood vessels or other internal organs.^[10]

Treatment in Clinical Trials

While standard treatments help many patients with Behçet’s syndrome manage their symptoms, researchers continue to investigate new therapies that might work better or cause fewer side effects. Clinical trials are the pathway through which these experimental treatments are carefully tested for safety and effectiveness. Understanding the basics of clinical research can help patients make informed decisions about whether participating in a trial might be right for them.

Understanding Clinical Trial Phases

Clinical trials typically proceed through three main phases before a new drug can be approved for general use. Phase I trials are small studies that focus primarily on safety—determining what dose can be given without causing unacceptable side effects. Phase II trials involve more patients and begin to evaluate whether the treatment actually works against the disease. Phase III trials are large studies that compare the new treatment to current standard treatments to see if it offers real advantages. This systematic approach helps ensure that only safe and effective treatments ultimately become available to patients.^[10]

Promising Approaches Under Investigation

Research into Behçet’s syndrome has accelerated in recent years as scientists gain a better understanding of the biological mechanisms driving the disease. Several innovative treatment strategies are being explored in clinical trials around the world.

The success of TNF inhibitors like infliximab and adalimumab in clinical practice has spurred interest in refining and expanding this approach. Researchers are studying optimal dosing strategies, exploring whether these medications can be safely stopped after achieving remission, and investigating combinations with other drugs. Clinical trials have demonstrated that infliximab, given as an intravenous infusion, can dramatically reduce eye inflammation and prevent vision loss in patients with severe uveitis who haven’t responded to conventional immunosuppressants. The drug appears to work by blocking the inflammatory cascade at a critical point, preventing the immune system from attacking blood vessels and other tissues.^[14]

Studies comparing different treatment approaches have also provided valuable information. For instance, research comparing TNF-α inhibitors with apremilast for treatment-resistant oral ulcers found that both approaches can be equally effective, giving doctors and patients more options to choose from based on individual circumstances.^[14]

Novel Biological Agents

Beyond TNF inhibitors, other biological therapies targeting different parts of the immune system are under investigation. Some trials are examining drugs that block interleukin-1 or interleukin-6, proteins involved in the inflammatory response. These medications have shown promise in treating other inflammatory diseases and may offer benefits for Behçet’s patients who don’t respond to current treatments.

Researchers are also studying drugs that target specific immune cells or inflammatory pathways unique to Behçet’s syndrome. For example, some experimental treatments aim to regulate the activity of certain white blood cells that appear to be overactive in people with this condition. By selectively dampening these cells without broadly suppressing the entire immune system, these therapies might provide better symptom control with fewer side effects.^[10]

Improved Formulations of Existing Drugs

Not all clinical research focuses on entirely new molecules. Some studies investigate better ways to deliver existing effective medications. For instance, researchers are exploring extended-release formulations that allow for less frequent dosing, topical preparations that deliver higher concentrations to affected tissues while minimizing systemic effects, and novel combinations of established drugs that might work synergistically.

Trial Locations and Eligibility

Clinical trials for Behçet’s syndrome are conducted in various locations around the world. Because the disease is more common in certain geographic areas—particularly along the historical “Silk Road” spanning from the Mediterranean through the Middle East to East Asia—many research centers in Turkey, Japan, Italy, and other countries with higher disease prevalence conduct clinical studies. However, trials also take place in the United States, other parts of Europe, and elsewhere.^[2][4]

Eligibility for specific trials depends on many factors, including disease severity, which organs are affected, previous treatments tried, and other medical conditions a patient might have. Generally, trial participants must be willing to undergo regular monitoring visits, be able to provide informed consent, and meet the specific inclusion criteria set by the researchers. Patients interested in clinical trials should discuss the possibility with their rheumatologist or other specialists, who can help identify appropriate studies and explain the potential risks and benefits of participation.^[10]

In some countries, specialized centers of excellence for Behçet’s disease exist where cutting-edge research is conducted alongside clinical care. For example, England has three NHS Centres of Excellence specifically for Behçet’s in London, Birmingham, and Liverpool. These centers not only provide expert diagnosis and treatment but also may offer access to the latest clinical trials.^[3][23]

What to Expect from Participation

Joining a clinical trial means becoming a partner in medical research. Participants typically receive very close monitoring and may have access to treatments that aren’t yet widely available. However, there are also potential downsides: experimental treatments might not work as hoped or could cause unexpected side effects, and trial protocols often require more frequent visits and tests than routine care. Some studies use placebo (inactive treatment) for comparison, meaning participants might not receive active medication for a period of time. All these factors should be carefully considered and discussed with healthcare providers and loved ones before enrolling.

Most Common Treatment Methods

• Topical Medications
  • Corticosteroid creams, gels, and ointments applied directly to mouth and genital ulcers
  • Special mouthwashes containing corticosteroids to relieve pain from oral sores
  • Eye drops with corticosteroids for mild eye inflammation
  • Triamcinolone acetonide for mouth ulcers and betamethasone for genital sores
• Anti-inflammatory Drugs
  • Colchicine to prevent recurrent mouth and genital ulcers and treat skin manifestations
  • Apremilast (Otezla), the first FDA-approved oral medication specifically for oral ulcers in Behçet’s
• Corticosteroids
  • Oral prednisone and other systemic corticosteroids for severe inflammation throughout the body
  • Typically used during acute flares and then gradually reduced
  • May be combined with other medications for a steroid-sparing effect
• Immunosuppressive Medications
  • Azathioprine as first-line therapy for eye disease and other manifestations
  • Cyclosporine and tacrolimus for severe eye inflammation
  • Cyclophosphamide for life-threatening complications involving blood vessels or the nervous system
  • Methotrexate and mycophenolate as alternative immunosuppressants
• Biological Therapies
  • TNF inhibitors including infliximab (Remicade) and adalimumab (Humira) for severe disease
  • Interferon-alfa for severe eye disease, used primarily in Europe and Japan
  • Targeted treatment of specific inflammatory pathways